ATE314063T1 - Valproinsäure zur behandlung von brustkrebs, dickdarmkrebs, kopf-hals-krebs, kleinzelligem lungenkarzinom und blutzellenkrebs in kombination mit bestrahlung - Google Patents
Valproinsäure zur behandlung von brustkrebs, dickdarmkrebs, kopf-hals-krebs, kleinzelligem lungenkarzinom und blutzellenkrebs in kombination mit bestrahlungInfo
- Publication number
- ATE314063T1 ATE314063T1 AT02777129T AT02777129T ATE314063T1 AT E314063 T1 ATE314063 T1 AT E314063T1 AT 02777129 T AT02777129 T AT 02777129T AT 02777129 T AT02777129 T AT 02777129T AT E314063 T1 ATE314063 T1 AT E314063T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer
- treatment
- combination
- radiation
- head
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 title 2
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 206010009944 Colon cancer Diseases 0.000 title 1
- 210000000601 blood cell Anatomy 0.000 title 1
- 208000029742 colonic neoplasm Diseases 0.000 title 1
- 201000010536 head and neck cancer Diseases 0.000 title 1
- 208000014829 head and neck neoplasm Diseases 0.000 title 1
- 230000005855 radiation Effects 0.000 title 1
- 208000000587 small cell lung carcinoma Diseases 0.000 title 1
- 229960000604 valproic acid Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000003964 Histone deacetylase Human genes 0.000 abstract 1
- 108090000353 Histone deacetylase Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 208000007660 Residual Neoplasm Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01121722A EP1293205A1 (de) | 2001-09-18 | 2001-09-18 | Valproinsäure und deren Derivate zur Kombinationsbehandlung von Krebs beim Menschen und zur Behandlung von Tumor-Metastasen und minimaler Resterkrankung |
| PCT/EP2002/010419 WO2003024442A2 (en) | 2001-09-18 | 2002-09-17 | Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE314063T1 true ATE314063T1 (de) | 2006-01-15 |
Family
ID=8178602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02777129T ATE314063T1 (de) | 2001-09-18 | 2002-09-17 | Valproinsäure zur behandlung von brustkrebs, dickdarmkrebs, kopf-hals-krebs, kleinzelligem lungenkarzinom und blutzellenkrebs in kombination mit bestrahlung |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050038113A1 (de) |
| EP (4) | EP1293205A1 (de) |
| JP (1) | JP2005512961A (de) |
| AT (1) | ATE314063T1 (de) |
| AU (1) | AU2002338716B2 (de) |
| CA (1) | CA2460713A1 (de) |
| CY (1) | CY1105552T1 (de) |
| DE (1) | DE60208397T2 (de) |
| DK (1) | DK1427403T3 (de) |
| ES (1) | ES2252519T3 (de) |
| WO (1) | WO2003024442A2 (de) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7250514B1 (en) | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7375228B2 (en) * | 2003-03-17 | 2008-05-20 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| WO2004103358A2 (en) * | 2003-05-21 | 2004-12-02 | Novartis Ag | Combination of histone deacetylase inhibitors with chemotherapeutic agents |
| EP1491188A1 (de) * | 2003-06-25 | 2004-12-29 | G2M Cancer Drugs AG | Topische Verwendung von Valproinsäure zur Behandlung von Hauterkrankungen |
| CN102349927A (zh) * | 2003-08-29 | 2012-02-15 | Hdac默克研究有限责任公司 | 联合治疗癌症的方法 |
| WO2005065681A1 (en) * | 2003-12-19 | 2005-07-21 | Takeda San Diego, Inc. | N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer |
| US20050137234A1 (en) * | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
| US7951780B2 (en) * | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
| US7642275B2 (en) | 2004-12-16 | 2010-01-05 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| NZ589276A (en) * | 2005-02-03 | 2012-06-29 | Topotarget Uk Ltd | Combination therapies using hdac inhibitors and erlotinib (tarceva) |
| US7869590B2 (en) * | 2005-04-12 | 2011-01-11 | Broadcom Corporation | Method and system for hardware accelerator for implementing f9 integrity algorithm in WCDMA compliant handsets |
| JP2008540574A (ja) | 2005-05-11 | 2008-11-20 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| SI1901729T1 (sl) | 2005-05-13 | 2012-05-31 | Topotarget Uk Ltd | Farmacevtske formulacije HDAC inhibitorjev |
| CA2615105A1 (en) * | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| CA2627923C (en) | 2005-11-10 | 2016-01-12 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer |
| CA2630334C (en) * | 2005-11-16 | 2013-07-23 | Universidad Nacional Autonoma De Mexico | Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer |
| RU2389484C2 (ru) * | 2005-11-18 | 2010-05-20 | Универсидад Насиональ Аутонома Де Мексико | Применение модифицирующих транскриптом агентов и химиотерапии или радиотерапии против рака |
| EP1976835A2 (de) * | 2006-01-13 | 2008-10-08 | Takeda San Diego, Inc. | Histondeacetylase-inhibitoren |
| ES2395401T3 (es) * | 2006-03-23 | 2013-02-12 | Tmrc Co., Ltd. | kit para la terapia del cáncer y composición farmacéutica para la terapia del cáncer |
| US9539303B2 (en) | 2006-04-24 | 2017-01-10 | Celgene Corporation | Treatment of Ras-expressing tumors |
| DE102006022877B4 (de) | 2006-05-15 | 2009-01-29 | Sartorius Stedim Biotech Gmbh | Verfahren zur Bestimmung der Viabilität von Zellen in Zellkulturen |
| US8957027B2 (en) | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
| US20080085874A1 (en) * | 2006-08-28 | 2008-04-10 | The Regents Of The University Of California | Small molecule potentiator of hormonal therapy for breast cancer |
| EP2091525A1 (de) * | 2006-12-06 | 2009-08-26 | Sapporo Medical University | Verstärkung der zellimmunität mit histon-deacetylase (hdac)-hemmern |
| GB0625283D0 (en) * | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
| EP2102230A2 (de) | 2006-12-29 | 2009-09-23 | Gloucester Pharmaceuticals, Inc. | Reinigung von romidepsin |
| GB2454118B (en) * | 2007-06-06 | 2010-06-02 | Univ Maryland | Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
| CN101868446A (zh) | 2007-09-25 | 2010-10-20 | 托波塔吉特英国有限公司 | 某些异羟肟酸化合物的合成方法 |
| JPWO2010064422A1 (ja) * | 2008-12-02 | 2012-05-10 | 静岡県公立大学法人 | ヒストン高アセチル化状態における光増感処理による腫瘍殺傷法 |
| US8491927B2 (en) | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
| CN103108648A (zh) | 2010-07-12 | 2013-05-15 | 细胞基因公司 | 罗米地辛固体形式及其用途 |
| US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
| KR101733189B1 (ko) | 2010-10-06 | 2017-05-08 | (주)아모레퍼시픽 | 손톱 또는 발톱 성장 촉진용 조성물 |
| HUE032100T2 (en) * | 2011-03-21 | 2017-08-28 | Valcuria Ab | A pharmaceutical composition comprising an HDAC inhibitor and a steroid and its use |
| AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
| AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
| NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
| JP6551963B2 (ja) * | 2014-05-14 | 2019-07-31 | 国立大学法人京都大学 | 巨核球前駆細胞の製造方法 |
| MX388409B (es) * | 2014-06-12 | 2025-03-19 | Cedars Sinai Medical Center | Composiciones y metodos para tratar canceres. |
| CA3175127A1 (en) | 2020-03-12 | 2021-09-16 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| GB202102606D0 (en) * | 2021-02-24 | 2021-04-07 | Univ Oxford Innovation Ltd | Treatment of ovarian cancer minimal residual disease |
| AU2022319362A1 (en) * | 2021-07-27 | 2024-02-29 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935450A (en) * | 1982-09-17 | 1990-06-19 | Therapeutical Systems Corporation | Cancer therapy system for effecting oncolysis of malignant neoplasms |
| CA1339034C (en) * | 1988-08-22 | 1997-04-01 | Paul A. Tremblay | Platinum complexes of single isomer neoalkyl acids |
| JPH0279969A (ja) * | 1988-09-19 | 1990-03-20 | Shigeyoshi Fujimoto | 細胞障害性ｔ細胞誘導及び活性化の方法 |
| FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| EP0632008B1 (de) * | 1993-06-01 | 1998-02-04 | Ono Pharmaceutical Co., Ltd. | Pentansäurederivate |
| US6300373B1 (en) * | 1993-09-10 | 2001-10-09 | American Biogenetic Sciences, Inc. | Antiproliferative and neurotrophic molecules |
| US5672746A (en) * | 1994-08-30 | 1997-09-30 | American Biogenetic Sciences, Inc. | Antiproliferative and neurotrophic molecules |
| US5786344A (en) * | 1994-07-05 | 1998-07-28 | Arch Development Corporation | Camptothecin drug combinations and methods with reduced side effects |
| ATE229810T1 (de) * | 1996-10-11 | 2003-01-15 | Univ California | Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen |
| US6110970A (en) * | 1997-03-11 | 2000-08-29 | Beacon Laboratories, Inc. | Nitrogen-containing oxyalkylene esters and uses thereof |
| US6110955A (en) * | 1997-03-11 | 2000-08-29 | Beacon Laboratories, Inc. | Metabolically stabilized oxyalkylene esters and uses thereof |
| US6043389A (en) * | 1997-03-11 | 2000-03-28 | Mor Research Applications, Ltd. | Hydroxy and ether-containing oxyalkylene esters and uses thereof |
| US5939455A (en) * | 1997-03-11 | 1999-08-17 | Beacon Laboratories, Inc. | Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives |
| US6124495A (en) * | 1997-03-11 | 2000-09-26 | Beacon Laboratories, Inc. | Unsaturated oxyalkylene esters and uses thereof |
| US6028102A (en) * | 1998-02-24 | 2000-02-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Anticonvulsant drugs and pharmaceutical compositions thereof |
| AU2337601A (en) * | 1999-12-23 | 2001-07-09 | Ontario Cancer Institute, The | Inhibition of gsk-3beta |
| EP1170008A1 (de) * | 2000-07-07 | 2002-01-09 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Valproinsäure und dessen Derivate als Inhibitoren der Histone deacetylase |
-
2001
- 2001-09-18 EP EP01121722A patent/EP1293205A1/de not_active Withdrawn
-
2002
- 2002-09-17 JP JP2003528538A patent/JP2005512961A/ja active Pending
- 2002-09-17 DK DK02777129T patent/DK1427403T3/da active
- 2002-09-17 EP EP05019659A patent/EP1602371A3/de not_active Withdrawn
- 2002-09-17 EP EP02777129A patent/EP1427403B8/de not_active Expired - Lifetime
- 2002-09-17 AU AU2002338716A patent/AU2002338716B2/en not_active Ceased
- 2002-09-17 DE DE60208397T patent/DE60208397T2/de not_active Expired - Lifetime
- 2002-09-17 CA CA002460713A patent/CA2460713A1/en not_active Abandoned
- 2002-09-17 WO PCT/EP2002/010419 patent/WO2003024442A2/en not_active Ceased
- 2002-09-17 ES ES02777129T patent/ES2252519T3/es not_active Expired - Lifetime
- 2002-09-17 AT AT02777129T patent/ATE314063T1/de active
- 2002-09-17 US US10/489,770 patent/US20050038113A1/en not_active Abandoned
- 2002-09-17 EP EP05101081A patent/EP1529527A3/de not_active Withdrawn
-
2006
- 2006-02-28 CY CY20061100277T patent/CY1105552T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1105552T1 (el) | 2010-07-28 |
| DK1427403T3 (da) | 2006-04-03 |
| EP1427403B8 (de) | 2006-03-22 |
| CA2460713A1 (en) | 2003-03-27 |
| EP1529527A2 (de) | 2005-05-11 |
| EP1427403B1 (de) | 2005-12-28 |
| ES2252519T3 (es) | 2006-05-16 |
| JP2005512961A (ja) | 2005-05-12 |
| WO2003024442A2 (en) | 2003-03-27 |
| US20050038113A1 (en) | 2005-02-17 |
| EP1602371A2 (de) | 2005-12-07 |
| WO2003024442A3 (en) | 2003-09-18 |
| DE60208397D1 (de) | 2006-02-02 |
| EP1293205A1 (de) | 2003-03-19 |
| EP1602371A3 (de) | 2006-11-15 |
| DE60208397T2 (de) | 2006-07-13 |
| AU2002338716B2 (en) | 2007-08-16 |
| EP1529527A3 (de) | 2005-05-25 |
| EP1427403A2 (de) | 2004-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60208397D1 (de) | Valproinsäure zur Behandlung von Brustkrebs, Dickdarmkrebs, Kopf-Hals-Krebs, kleinzelligem Lungenkarzinom und Blutzellenkrebs in Kombination mit Bestrahlung | |
| ATE442142T1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
| HUP0402217A2 (hu) | Platinaszármazékot tartalmazó gyógyászati készítmények | |
| DE50310516D1 (de) | Fredericamycin-derivate | |
| ATE413183T1 (de) | Verwendung von laminarin in der behandlung von krebs | |
| ATE426617T1 (de) | Therapeutische und diagnostische anti-hsp 70- antikírper | |
| DE602004016376D1 (de) | Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs | |
| YU73301A (sh) | eNOS MUTACIJE,NJIHOVA UPOTREBA ZA PRIPREMU LEKA ZA GENSKU TERAPIJU I POSTUPCI TERAPEUTSKOG SKRININGA | |
| NZ515388A (en) | Polynucleotides and polypeptides used to stimulate leukocyte growth and to modulate angiogenesis and treat neurological conditions | |
| DE60330914D1 (de) | Arzneimittel mit shikonin als wirkstoff | |
| KR102464528B1 (ko) | 웨어러블 광 조사기 | |
| ATE535237T1 (de) | Verwendung von fts zur behandlung von malignen erkrankungen | |
| DE602004016754D1 (de) | Kombinationstherapie gegen krebserkrankungen mit azd2171 und zd1839 | |
| EE200200549A (et) | Jagatud doosi teraapia veresooni kahjustava aktiivsusega | |
| DE602005017590D1 (de) | Kombinationstherapie mit azd-2171 | |
| EA200401454A1 (ru) | Новая комбинация из обратимо действующих ингибиторов протонного насоса и используемых в терапии дыхательных путей лекарственных веществ, предназначенных для лечения респираторных заболеваний | |
| CN101693106B (zh) | 金属硫蛋白在制备治椎间盘突出及骨质增生症的药中的应用 | |
| ATE239492T1 (de) | Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen | |
| RU2015127037A (ru) | Комбинации ингибитора pi3k/akt с ингибитором her3/egfr и способы их применения | |
| RU2554504C1 (ru) | Способ лечения лекарственной сиалоаденопатии | |
| IL153586A0 (en) | Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer | |
| PL190404B1 (pl) | Środek farmaceutyczny działający przeciwko nowotworom, mikroorganizmom chorobotwórczym i chorobom inwazyjnym | |
| RU2007119229A (ru) | Способ фотодинамической терапии опухолей | |
| Bychkovsky et al. | Drugs based on modified polysaccharides for the local chemotherapy of malignant tumors | |
| GR20030100323A (el) | Στοματοδιασπειρωμενα δισκια φλουοξετινης ΄η και αλατων αυτης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1427403 Country of ref document: EP |